SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.04
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.60

24 Mar
2026

-0.070

OPEN

$2.72

-2.62%

HIGH

$2.72

14,909,428

LOW

$2.60

TARGET
$3.23 24.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 5.1 6.3 xxx
DPS (cps) xxx 1.8 4.1 xxx
EPS Growth xxx 100.0% 25.3% xxx
DPS Growth xxx 82.7% 100.0% xxx
PE Ratio xxx N/A 41.8 xxx
Dividend Yield xxx N/A 1.5% xxx
Div Pay Ratio(%) xxx 35.6% 64.7% xxx

Dividend yield today if purchased 3 years ago: 2.90%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.68

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx5.1
DPS All xxxxxxxxxxxxxxx1.8
Sales/Revenue xxxxxxxxxxxxxxx14,404.4 M
Book Value Per Share xxxxxxxxxxxxxxx40.6
Net Operating Cash Flow xxxxxxxxxxxxxxx598.8 M
Net Profit Margin xxxxxxxxxxxxxxx8.83 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-
Return on Assets xxxxxxxxxxxxxxx-
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-
Free Cash Flow ex dividends xxxxxxxxxxxxxxx60.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx194 M
Long Term Debt xxxxxxxxxxxxxxx1,877 M
Total Debt xxxxxxxxxxxxxxx2,071 M
Goodwill - Gross xxxxxxxxxxxxxxx3,617 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx139 M
Price To Book Value xxxxxxxxxxxxxxx7.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx57.6 M
Capex % of Sales xxxxxxxxxxxxxxx0.40 %
Cost of Goods Sold xxxxxxxxxxxxxxx10,948 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,606 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx80 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

27/02/2026

1

Buy

$3.35

28.85%

Sigma Healthcare’s 1H26 proforma sales rose 14.9% on the prior year and earnings (EBIT) increased 18.7%, broadly in line with consensus but below the UBS forecast. The earnings margin expandied by 34bps to 10.6%.

Chemist Warehouse Australia delivered double-digit like-for-like growth of 15%, moderating slightly but remaining above the broker's expectation, supported by network expansion and GLP-1 demand.

Gross margin expansion was modest at 8bps, assess the analysts, given mix impacts. Operating expenses reflected integration and international growth investment, notes the broker, with $100m in synergies reiterated.

UBS lowers its target price to $3.35 from $3.40 and retains a Buy rating.

FORECAST
UBS forecasts a full year FY26 dividend of 4.00 cents and EPS of 6.00 cents.
UBS forecasts a full year FY27 dividend of 5.00 cents and EPS of 7.00 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

05/03/2026

1

Upgrade to Buy from Overweight

$3.60

38.46%

Sigma Healthcare posted first half earnings that were in line with expectations albeit the composition was different to what Jarden anticipated. Sales were ahead of forecasts while margin expansion was softer.

Going forward, the broker surmises the risks are to the upside for earnings with the international roll-out and synergies on track. The main challenge is to confidently forecast revenue outcomes going forward, as well as leverage. 

Forecasts are largely unchanged and the broker, liking the health exposure, market position and high incremental returns on capital, upgrades to Buy from Overweight. Target of $3.60 is unchanged.

FORECAST
Jarden forecasts a full year FY26 dividend of 3.80 cents and EPS of 6.40 cents.
Jarden forecasts a full year FY27 dividend of 4.60 cents and EPS of 7.70 cents.
Access Extra Coverage Research History >

SIG STOCK CHART

FNArena News on SIG

1
Rudi’s View: Make Today’s Crisis Your Opportunity

10:00 AM - Rudi's View
2
Rudi’s View: Top Picks & Conviction Buys

Mar 19 2026 - Rudi's View
3
Rudi’s View: Oil, Inflation, Growth & Stagflation

Mar 18 2026 - Rudi's View
4
Rudi’s View: Post-February Conviction Calls

Mar 12 2026 - Rudi's View
5
Australian Broker Call *Extra* Edition – Mar 12, 2026

Mar 12 2026 - Daily Market Reports

Latest Health & Nutrition News

1
Sigma Healthcare’s Four Pillars Of Growth

Aug 29 2025 - Australia
2
Sigma Healthcare: Synergies, Margins In Focus

Jun 19 2025 - Australia
3
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
4
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
5
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
6
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
7
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
8
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
9
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
10
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports